bioAffinity Tech (BIAF)
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung u...
- Open
- 0.4900
- High
- 0.4900
- Low
- 0.4700
- Prev. Close
- 0.4860
- Volume
- 56.33K
- Turnover
- 26.82K
- Avg Price
- 0.4761
- Bid/Ask Ratio
- 78.95%
- Amplitude
- 4.12%
- 52wk High
- 13.5000
- Volume Ratio
- 0.24
- Turnover Ratio
- 1.66%
bioAffinity Tech Analyst Rating
View moreForecast & Rating
Aug 21, 2025Price forecast
$180.0037979.16%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · Aug 7 at 03:51 PM
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary
- PUBT · Aug 7 at 07:02 AM
bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 million
- StockTitan · Aug 6 at 11:00 PM
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung | BIAF Stock News
- Global Report · Aug 5 at 04:13 AM
Index Additions, Acquisitions, and Delisting Risks: This Week's Moves in 10 Niche Equities
- Global Report · Aug 4 at 04:17 AM
Big Tech's Infrastructure Spree and the Old Economy's Comeback
- Tip Ranks · Jul 31 at 04:54 PM
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice
